Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma

By afschroeder • July 14, 2026

Tan CR, Gordan L, Richter J, DiLeo R, Mewawalla P, Larson S, Davies F, Oveisi D, Gupta-Werner N, Medhekar R, Yin X, Cortoos A, Armoon M, Thompson-Leduc P, Rahman A, Tardif-Samson A, Vanden Eynde C, Reitan J, Milkovich G, Bubalo J, Forman A, Bryan B, Sborov D, Kaila S, Usmani S. Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma. Future Oncol. 2026 Jul 14:1-9. doi: 10.1080/14796694.2026.2698699. Epub ahead of print. PMID: 42444515.

Tags: chart review, daratumumab, frontline, Hematology/Oncology, Multiple myeloma, Progression-free survival, Publications, real-world, transplant-eligible

Carboplatin Plus Mirvetuximab Soravtansine In Platinum-Sensitive Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial

Konecny GE, Lim PC, Santin AD, Gilbert L, Alvarez Secord A, Bessette P, Matulonis UA, Sen J, Hong J, Lytle GE, Bako E, Spunt SL,[...]

Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer. Reply

O'Reilly EM, Wolpin BM, Wainberg ZA. Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer. Reply. N Engl J Med. 2026 Oct 22;395(16):1662. doi: 10.1056/NEJMc2611022. PMID: 42906097.

Actionable genetic landscape and dynamics in circulating DNA from 12,827 patients with metastatic breast cancer

Leshchiner I, Medford AJ, Cha J, Kiedrowski LA, Niemierko A, Keenan JC, Dai CS, Spring LM, Moy B, Wander SA, Vidula N, Isakoff SJ, Juric[...]